Short communicationContrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus
Introduction
The human cytomegalovirus (CMV) DNA polymerase, encoded by the UL54 (pol) gene, is the target for all current systemic CMV drugs, including ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV). A considerable diversity of mutations in pol can confer resistance to any or all of these drugs, although GCV resistance usually begins with mutations in the viral UL97 kinase gene.1 Because they confer different levels of resistance and cross-resistance, over 30 individual pol mutations have been characterized by recombinant phenotyping (marker transfer), a process in which they are transferred in isolation to reference drug sensitive CMV strains to determine the resulting level of resistance to each drug.2, 3, 4 The results are used for genotypic CMV resistance testing, where the UL97 and pol DNA sequences amplified from clinical specimens are checked for mutations known to confer drug resistance. Yet new mutations continue to be identified, and some published ones remain uncharacterized, resulting in less reliable interpretations of drug resistance based on similarities with known mutations. The traditional phenotypic approach of testing clinical isolates directly for drug sensitivity in cell culture is limited by current clinical laboratory practices that do not provide a live viral isolate, and the technical complexity of such assays. Continuing our practice of providing recombinant phenotyping data where they are lacking, we report here on three mutations at an exonuclease domain of pol that illustrate the divergent phenotypes that can result from different mutations at the same locus.
Section snippets
Methods
Strains and procedures for performing recombinant phenotyping have been published.5 Briefly, reference strain T2211 was derived from standard strain AD169 by introducing unique restriction sites in pol and UL97, along with a secreted alkaline phosphatase (SEAP) expression cassette at US6, which enabled viral quantitation by assay of supernatant SEAP activity using a chemiluminescent substrate. PCR products containing the desired mutations were created by using specific mutagenic primers and
Results
CMV pol mutations at codons I521T, P522A and P522L in the exonuclease III domain were studied. Mutation I521T was published as part of a genotype of multiple UL97 and pol mutations in a pediatric stem cell recipient who developed multi-drug resistant CMV and fatal CMV encephalitis.6 More recently, another pediatric stem cell recipient in Denver received 7 months of GCV treatment and had recurrent low-level CMV DNA in the peripheral blood, which contained pol mutation I521T and UL97 mutation
Discussion
The interpretation of CMV DNA polymerase drug resistance mutations is complicated by their diversity and a track record of suspected resistance phenotypes that were not subsequently confirmed by recombinant phenotyping, including mutations at codons 515, 737, 845 and 971.3, 4, 9 The three mutations studied here are located in the exonuclease III domain, as recognized by sequence homology to the herpes simplex DNA polymerase structure.10 Based on several established resistance mutations in this
Acknowledgements
This work was supported by NIH grant AI39938 and Department of Veterans Affairs research funds. Daniel Mitchell and Laura Van Wechel provided technical assistance.
References (10)
- et al.
Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes
Blood
(2000) - et al.
A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome
J Heart Lung Transplant
(2007) - et al.
Crystal structure of the herpes simplex virus 1 DNA polymerase
J Biol Chem
(2006) - et al.
Human cytomegalovirus resistance to antiviral drugs
Antimicrob Agents Chemother
(2005) - et al.
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments
J Virol
(1998)
Cited by (31)
Application of the ViroKey® SQ FLEX assay for detection of cytomegalovirus antiviral resistance
2023, Journal of Clinical VirologyCombination therapy as an effective tool for treatment of drug-resistant viral infections
2020, Combination Therapy against Multidrug ResistanceHerpesvirus DNA polymerases: Structures, functions and inhibitors
2017, Virus ResearchIdentification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance
2016, Antiviral ResearchCitation Excerpt :The results of this study will help to understand the molecular mechanisms of HCMV drug-resistance and increases the number of mutations that can now be detected by genotypic assays. Patient 1 is an 11-year old stem-cell transplant recipient (D−/R+) from our institution who developed a disseminated HCMV-infection during conditioning (Eckle et al., 2000; Chou et al., 2008; Cihlar et al., 1998; Fischer et al., 2013; Chou et al., 1995c; Fischer et al., 2015). Since the patient did not respond to GCV, therapy was switched to FOS 100 days post transplantation.
Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay
2015, Journal of Clinical VirologyCitation Excerpt :Mutation D515E alone showed only moderate GCV-resistance (ratio 2.4). Mutation I521T has already been published [10] but was tested in our PRA since it is part of the triple mutation. Ratios were 2.1 for GCV, 4.9 for CDV and 0.98 for FOS.